Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/68851
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3648]
Metadata
Show full item record
HIV DNA LEVELS IN PERSONS WHO ACQUIRED HIV IN THE SETTING OF LONG-ACTING CABOTEGRAVIR FOR HIV PREVENTION: ANALYSIS OF CASES FROM HPTN 083 AND 084
Author
Fogel, Jessica M.
Persaud, Deborah
Piwowar-Manning, Estelle
Richardson, Paul
Szewczyk, Joseph
Marzinke, Mark A.
Wang, Zhe
Guo, Xu
McCauley, Marybeth
Farrior, Jennifer
Tran, Ha Viet
Ungsedhapand, Chaiwat
Mathew, Carrie-Anne
Mpendo, Juliet
Rinehart, Alex R.
Rooney, James F.
Cohen, Myron S.
Hanscom, Brett
Grinsztejn, Beatriz
Hosseinipour, Mina C.
Delany-Moretlwe, Sinead
Landovitz, Raphael J.
Eshleman, Susan H.
Persaud, Deborah
Piwowar-Manning, Estelle
Richardson, Paul
Szewczyk, Joseph
Marzinke, Mark A.
Wang, Zhe
Guo, Xu
McCauley, Marybeth
Farrior, Jennifer
Tran, Ha Viet
Ungsedhapand, Chaiwat
Mathew, Carrie-Anne
Mpendo, Juliet
Rinehart, Alex R.
Rooney, James F.
Cohen, Myron S.
Hanscom, Brett
Grinsztejn, Beatriz
Hosseinipour, Mina C.
Delany-Moretlwe, Sinead
Landovitz, Raphael J.
Eshleman, Susan H.
Affilliation
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pediatrics. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pediatrics. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA / Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, Maryland, USA.
Fred Hutchinson Cancer Center. Seattle, Washington, USA.
Fred Hutchinson Cancer Center. Seattle, Washington, USA.
FHI 360. Durham, North Carolina, USA.
FHI 360. Durham, North Carolina, USA.
The University of North Carolina-Vietnam. Hanoi City, Vietnam.
U.S. Centers for Disease Control and Prevention. Division of HIV Prevention. Atlanta, Georgia, USA / Thailand Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration. Division of HIV Prevention. Nonthaburi, Thailand.
University of the Witwatersrand. Wits RHI. Johannesburg, South Africa.
Uganda Virus Research Institute-International AIDS Vaccine Initiative HIV Vaccine Program. Entebbe, Uganda.
ViiV Healthcare. Research Triangle Park, North Carolina, USA.
Gilead Sciences. Foster City, California, USA.
University of North Carolina. Department of Medicine. Chapel Hill, North Carolina, USA.
Fred Hutchinson Cancer Center. Seattle, Washington, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST e AIDS. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Department of Medicine. Chapel Hill, North Carolina, USA.
University of the Witwatersrand. Wits RHI. Johannesburg, South Africa.
University of California. Center for Clinical AIDS Research & Education. Los Angeles, Los Angeles, California, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pediatrics. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pediatrics. Baltimore, Maryland, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA / Johns Hopkins University School of Medicine. Department of Medicine. Baltimore, Maryland, USA.
Fred Hutchinson Cancer Center. Seattle, Washington, USA.
Fred Hutchinson Cancer Center. Seattle, Washington, USA.
FHI 360. Durham, North Carolina, USA.
FHI 360. Durham, North Carolina, USA.
The University of North Carolina-Vietnam. Hanoi City, Vietnam.
U.S. Centers for Disease Control and Prevention. Division of HIV Prevention. Atlanta, Georgia, USA / Thailand Ministry of Public Health-U.S. Centers for Disease Control and Prevention Collaboration. Division of HIV Prevention. Nonthaburi, Thailand.
University of the Witwatersrand. Wits RHI. Johannesburg, South Africa.
Uganda Virus Research Institute-International AIDS Vaccine Initiative HIV Vaccine Program. Entebbe, Uganda.
ViiV Healthcare. Research Triangle Park, North Carolina, USA.
Gilead Sciences. Foster City, California, USA.
University of North Carolina. Department of Medicine. Chapel Hill, North Carolina, USA.
Fred Hutchinson Cancer Center. Seattle, Washington, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST e AIDS. Rio de Janeiro, RJ, Brasil.
University of North Carolina. Department of Medicine. Chapel Hill, North Carolina, USA.
University of the Witwatersrand. Wits RHI. Johannesburg, South Africa.
University of California. Center for Clinical AIDS Research & Education. Los Angeles, Los Angeles, California, USA.
Johns Hopkins University School of Medicine. Department of Pathology. Baltimore, Maryland, USA.
Abstract
We evaluated HIV DNA levels in individuals who received long-acting cabotegravir (CAB-LA) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis in the HPTN 083 and 084 trials and had HIV DNA testing performed to help determine HIV status. HIV DNA testing was performed using peripheral blood mononuclear cell (PBMC) samples collected after a reactive HIV test was obtained at a study site. DNA was quantified using droplet digital PCR (lower limit of detection [LLOD]: 4.09 copies/million PBMCs). Final HIV status and the timing of the first HIV-positive visit were determined by an independent adjudication committee based on HIV test results from real-time site testing and retrospective testing at a centralized laboratory. HIV DNA testing was performed for 133 participants [21 HIV-positive (7 CAB-LA arm, 14 TDF/FTC arm) and 112 HIV-negative; 1-6 tests/person]. For persons with HIV, the time between the first HIV-positive visit and collection of the first sample for DNA testing was a median of 81 days for those receiving CAB-LA (range 41-246) and 11 days for those receiving TDF/FTC (range 3-127). Four (57.1%) of the seven CAB-LA cases with infection had a low initial DNA result [three detected <LLOD; one near the LLOD (4.2 copies/106 PBMCs); in 2/4 cases, the DNA level was still <10 copies/106 PBMCs ≥40 weeks after the first HIV-positive visit. In contrast, only 3/14 (21.4%) of the TDF/FTC cases had a low or negative initial DNA test result (one not detected; two <10 copies/106 PBMCs). In this study, the time between the first HIV-positive visit and the first DNA test was longer in the CAB-LA cases than the TDF/FTC cases. Despite this difference, low or undetectable DNA levels were more frequently observed in the CAB-LA cases. This suggests that CAB-LA exposure may limit seeding of the HIV reservoir in early infection.
Share